The updated Pfizer-BioNTech and Moderna monovalent XBB.1.5 COVID-19 2023-2024 vaccines were recently approved and authorized by the United States Food and Drug Administration (FDA), based on studies that showed a stronger immune response against current circulating COVID-19 strains than previous versions of the vaccine. As would be expected, since there is no actual virus in the mRNA vaccines, they have similar safety profiles to previously available mRNA vaccines. The process for creating these updated vaccines is no different than for the original COVID-19 vaccines, and is comparable to the annual revision of the annual flu vaccine to match circulating strains for that year’s flu season. These updated vaccines are expected to provide improved protection against COVID-19 from the currently circulating variants. The Novavax COVID-19 vaccine should also be available in a revised form to target newer COVID-19 strains, and uses a more “traditional” protein-based format, but it has not yet been approved for use by the FDA. It is recommended that all pregnant women receive any of the available vaccines as soon as possible, especially if their last vaccine was last year.